Reduced risk of heart failure hospitalizations in patients with type 2 diabetes using SGLT-2 inhibitors

Can sitagliptin help in latent autoimmune diabetes?

Posted by Medivizor on Feb 28, 2021 in Diabetes mellitus | In a nutshell This review focused on the effect of sodium-glucose cotransporter-2 inhibitors (SGLT-2i) on heart failure hospitalization in patients with type 2 diabetes (T2D). This analysis showed that

Read More Reduced risk of heart failure hospitalizations in patients with type 2 diabetes using SGLT-2 inhibitors

DPP-4 Inhibitors and Respiratory Infection: A Systematic Review and Meta-analysis of the Cardiovascular Outcomes Trials

Prediabetes, Diabetes, and the Risk of All-Cause and Cause-Specific Mortality in a Japanese Working Population: Japan Epidemiology Collaboration on Occupational Health Study

From before the coronavirus disease 2019 (COVID-19) pandemic, the effect of dipeptidyl peptidase 4 inhibitors (DPP-4i) on respiratory infections (RI) remains unclear. The meta-analysis of Yang et al. (1) specifically assessed the risk of infection with DPP-4i. However, cardiovascular outcomes

Read More DPP-4 Inhibitors and Respiratory Infection: A Systematic Review and Meta-analysis of the Cardiovascular Outcomes Trials

Comparative Effectiveness and Safety of Sodium–Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older Adults

Prediabetes, Diabetes, and the Risk of All-Cause and Cause-Specific Mortality in a Japanese Working Population: Japan Epidemiology Collaboration on Occupational Health Study

Comparative Effectiveness and Safety of Sodium–Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older Adults Elisabetta Patorno, Ajinkya Pawar, Lily G. Bessette, Dae H. Kim, Chintan Dave, Robert J. Glynn, Medha N. Munshi, Sebastian Schneeweiss, Deborah J.

Read More Comparative Effectiveness and Safety of Sodium–Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older Adults

Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors

1.Centers for Disease Control and Prevention. National Diabetes Statistical Report. Centers for Disease Control and Prevention https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf (2020).2.Koye, D. N., Magliano, D. J., Nelson, R. G. & Pavkov, M. E. The global epidemiology of diabetes and kidney disease. Adv. Chronic

Read More Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors

Sodium–Glucose Cotransporter 2 Inhibitors and the Short-term Risk of Breast Cancer Among Women With Type 2 Diabetes

Adolescent Hypertension and Risk for Early-Onset Type 2 Diabetes: A Nationwide Study of 1.9 Million Israeli Adolescents

Sodium–glucose cotransporter 2 (SGLT2) inhibitors are second- to third-line antidiabetes drugs that have been shown to have cardiovascular benefits. However, in premarketing trials of the SGLT2 inhibitor dapagliflozin, there were numerical imbalances in breast cancer events compared with placebo; all

Read More Sodium–Glucose Cotransporter 2 Inhibitors and the Short-term Risk of Breast Cancer Among Women With Type 2 Diabetes

Comparing the effects of SGLT-2 inhibitors and other diabetes medications on kidney health

Does testosterone treatment improve diabetes control in men with type 2 diabetes and low testosterone?

Posted by Medivizor on Dec 6, 2020 in Diabetes mellitus | In a nutshell This study used real-world data to compare SGLT-2 inhibitors versus other medications for patients with type 2 diabetes (T2D). It found that SGLT-2 inhibitors led to

Read More Comparing the effects of SGLT-2 inhibitors and other diabetes medications on kidney health

Do SGLT2 inhibitors with or without metformin improve heart and kidney health?

Does testosterone treatment improve diabetes control in men with type 2 diabetes and low testosterone?

Posted by Medivizor on Nov 29, 2020 in Diabetes mellitus | In a nutshell This review looked at how SGTL2 inhibitors with or without metformin (Glucophage) affect heart and kidney health for patients with type 2 diabetes (T2D). It found

Read More Do SGLT2 inhibitors with or without metformin improve heart and kidney health?